Cetera Investment Advisers
CSTL icon

Cetera Investment Advisers’s Castle Biosciences CSTL Stock Holding History

Cetera Investment Advisers’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206K Sell
8,632
-576
-6% -$12.8K ﹤0.01% 4474
2026
Q1 		$226K Buy
9,208
+273
+3% +$8.94K ﹤0.01% 4202
2025
Q4 		$348K Buy
+8,935
New +$288K ﹤0.01% 3764

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cetera Investment Advisers's CSTL Position: Q2 2026 in Review

Cetera Investment Advisers reduced its Castle Biosciences (CSTL) stake by 6.3% in Q2 2026, selling an estimated $12.8K and leaving 8,632 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #4474.

Cetera Investment Advisers first reported a position in CSTL in Q4 2025 and has held it in 3 quarters since. The position peaked at $348K in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Cetera Investment Advisers held 8,632 shares of Castle Biosciences worth $206K as of Q2 2026.
  • Cetera Investment Advisers sold 576 Castle Biosciences shares in Q2 2026, an estimated $12.8K.
  • Castle Biosciences made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #4474 holding.
  • Cetera Investment Advisers first reported a position in Castle Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Cetera Investment Advisers's Castle Biosciences position peaked at $348K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.